share_log

Reported Saturday, Syndax's Revuforj (Revumenib) Achieves High Response Rates In Acute Leukemia Trials, Presents Compelling Data At ASH 2024

土曜日に報告されたSyndaxのRevuforj(Revumenib)が急性白血病の試験で高い応答率を達成し、ASH 2024で説得力のあるデータを提示しました

Benzinga ·  12/09 16:38
  • 82% ORR (27 of 33 pts) and 48% CR/CRh (16 of 33 pts) in SAVE trial studying revumenib in combination with venetoclax and decitabine/cedazuridine in R/R AML –
  • 64% ORR (62 of 97 pts) and 23% CR/CRh (22 of 97 pts) with high rates of MRD negativity and ability to proceed to HSCT in expanded dataset of Ph 2 R/R KMT2Ar acute leukemia patients in AUGMENT-101 –
  • Responses were rapid, durable and observed across all major subgroups in expanded dataset of Ph 2 R/R KMT2Ar acute leukemia patients in AUGMENT-101 –
  • Latest data highlight the compelling clinical profile of revumenib and support advancement into combination trials in the frontline setting –
これらの内容は、情報提供及び投資家教育のためのものであり、いかなる個別株や投資方法を推奨するものではありません。 更に詳しい情報
    コメントする